ANAB – anaptysbio, inc. (US:NASDAQ)

News

Actym Therapeutics Appoints Thomas Smart as CEO [Yahoo! Finance]
Actym Therapeutics Appoints Thomas Smart as CEO
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com